Lupin announced the receipt of the Establishment
Inspection Report (EIR) from the USFDA for its Aurangabad facility. The facility was inspected by the USFDA
between 06 May 2019 and 15 May 2019.
Lupin's Aurangabad facility is involved in the manufacture of Oral Solid Dosage, Oral Liquid and Powder for Oral Suspension products for the US Market, WHO/Global Institution markets and the India market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
